Dr. Daniel Von Hoff, MD FACP
The Seena Magowitz Foundation is fortunate to be associated with Dr. Von Hoff, the Director of TGen's Clinical Translational Research Division. He is world renowned for his contributions to pancreatic cancer research and the development of revolutionary cancer drugs including gemcitabine, an anti-cancer agent that significantly improves the survival rates of patients with pancreatic cancer.
Dr. Daniel Von Hoff has coordinated the formation of a world-wide team of experts solely focused on pancreatic research. This Pancreatic Cancer Research Team (PCRT) of physicians and scientists shares knowledge and resources with a commitment to the rapid advancement in pancreatic research using the corroborative knowledge to initiate clinical trials allowing patients immediate access to newly developed therapies.
Dr. Von Hoff: Pancreatic Cancer Research
Does This Man Ever Sleep?
Dr.Von Hoff is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center's Cancer Therapeutics Program, Executive Vice President, Translational Genomics Research Institute (TGen), Director, TGen's Translational Drug Development Division and Head, Pancreatic Cancer Research Program. He is also Chief Scientific Officer for US Oncology.
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies.
His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. He and his laboratory are now concentrating on discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 - March 2010.
Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics.
He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
More About Dr. Von Hoff
